In compliance with out-of-hospital patient transport standards such as EN1789, EN13718-1, IEC60601-1-12 and U.S. military standards, N1 is a highly competent solution for various out-of-hospital transport settings both on land and in air. The N1's exceptional reliability and strong performance enhance your confidence to provide seamless patient care during transport no matter intra or out of hospital. One monitor, Multiple solutions Mirror Mode Two-way screen or remote control functionality and viewing on both the 19" external display and the N1 unit - simultaneously. benevision-n1-fig2-2-pc BeneVision N1 as a Transport Monitor Enhanced data analysis greatly improves parameters' accuracy and anti-interference ability. Its fully integrated sidestream CO2 module monitors the patient's breathing situation by connecting with sampling line directly, freeing caregivers from the shackles of expanding external modules for transport. One monitor, Multiple solutions Mirror Mode Two-way screen or remote control functionality and viewing on both the 19" external display and the N1 unit - simultaneously. benevision-n1-fig2-2-pc BeneVision N1 as a Transport Monitor Enhanced data analysis greatly improves parameters' accuracy and anti-interference ability. Its fully integrated sidestream CO2 module monitors the patient's breathing situation by connecting with sampling line directly, freeing caregivers from the shackles of expanding external modules for transport. benevision-n1-fig2-1-pc BeneVision N1 as a Multi-Parameter Module Slide directly into the module slot or SMR of the N-Series monitor providing an expansive set of parameter measurements. When combined with our additional advanced parameter modules, this solution fits even the highest level of critical care environments. benevision-n1-fig2-3-pc Companion Mode Connect with N-Series host monitor via cable connection to N1 dock and have the ability for dual-screen monitoring and bi-directional control of the bedside monitor - expanding slot space for more advanced parameters and enhanced ICU workflow. Patient-Centric Data Collection When connected to a bedside patient monitor, advanced parameters collected from the host monitor such as AG and BIS, etc., will also be stored in N1 with trend data and alarm events reviewable even when it is disconnected.

With state-of-the-art screen technology, BeneVision N Series patient monitors deliver clear, multi-color, wide-format displays for users to capture and review information at a glance. With multi-touch operation, users can control the monitor and review patient data quickly and easily. BeneVision N Series provides the world's best monitoring technologies for you, with new applications being developed. Perfect hemodynamic monitoring solution, not only provides a variety of measurement methods, ICG, PiCCO, ScvO2, C.O., but also provides comprehensive analysis tool – HemoSight™. HemoSight™ focuses on hemodynamic treatment process, and provides appropriate tools for each stage. Advanced modular regional tissue oxygenation measurement -- INVOS rSO2. Volumetric capnography & metabolic measurement help to evaluate the adequacy of ventilation and determine the ventilator setting effectively, and improve the safety of weaning and extubation. Powerful Clinical Assistive Applications (CAAs) to support efficient decision making when time is critical. Each CAA focuses on major clinical workflow challenges that individual departments face. Solutions optimized for each point of care At every point of care, such as ICU, CCU, NICU, OR, PACU, ER, BeneVision N Series patient monitors always provide a suitable solution to meet your clinical needs for monitoring your patient's status anywhere, anytime, even on your way through mobile devices. With excellent transport solution, BeneVision N Series patient monitor brings a smooth workflow and safe data management through the entire care process. BeneVision takes less time to operate, and helps you understand the patient's variables quickly. With HL7,BeneVision N Series patient monitors can directly connect to the hospital clinical network.BeneVision N12 is capable of monitoring multiple parameters simultaneously both at bedside and during transport. IT structure designed for seamless connectivity Mindray patient monitoring system incorporates extensive network adaptability to integrate with the hospital's current network infrastructure, ensuring that critical data is on hand for clinical decision making - and is integrated with the patient record. Mindray's central station and eGateway further enhances the connectivity of BeneVision to your clinical world. Bedside devices data and other clinical systems data are shared to support your diagnosis and clinical decisions.

Mindray believes the best way to predict the future is to create it. The revolutionary BeneVision N22/N19 is designed to optimize user experience by satisfying all your clinical demands. With visionary-stimulating design, benchmarking ease of use, confidence-maximizing innovations and workflow-transforming interoperability, BeneVision N22/N19 is creating tomorrow’s monitoring perspective today. The design excellence of BeneVision N22/N19 has great originality to lead your perspective. A seamless outlook optimizes your monitoring experience with super large touchscreen, cool rotatable landscape & portrait layout, ultra slim main unit as well as plug-n-play modules. An ingenious user interface including multi-window flat menus, infographic alarm indications and online user guide offers extremely intuitive patient data and ultimate ease-of-use, while auto screen brightness always keeps patient in mind. Benefitting from cutting-edge clinical measurements, such as rSO2, ICG, PiCCO, AG, RM, BIS, NMT, and state-of-art clinical decision support tools, such as HemoSightTM, ST GraphicTM, DSA, BeneVision N22/N19 enhances your clinical confidence to the max and helps you make easier and faster clinical decisions. The connectivity capabilities of BeneVision N22/N19 fit seamlessly into your clinical workflow for paperless future. Revolutionary iView clinical informatics workstation brings all intelligence (PACS, LIS, EMR, etc) on screen at point of care for one-stop diagnosis. Industry-leading BeneLink integrates all bedside devices to the monitor realtimely and facilitates centralized data management.

Buy AccuTest H Pylori AB Rapid Card Test (50 Tests) Online from Accurex. The Helicobacter Pylori is a lateral flow chromatographic immunoassay for the qualitative detection of antibodies to H.pylori in human Whole Blood/Serum/Plasma. H Pylori test provides an aid in the diagnosis of infection with H.pylori. H.pylori is implicated in the etiology of a variety of gastrointestinal diseases, including duodenal and gastric ulcer, non-ulcer dyspepsia and active and chronic gastritis. h pylori symptoms are an ache or burning pain in your stomach (abdomen), Nausea, Loss of appetite, Frequent burping, Bloating & Unintentional weight loss NTENDED USE The H.pylori Antibody Rapid Test Card is a lateral flow chromatographic immunoassay for the qualitative detection of antibodies to H.pylori in human Whole Blood/Serum/Plasma. It provides an aid in the diagnosis of infection with H.pylori. INTRODUCTION H.pylori is implicated in the etiology of a variety of gastrointestinal diseases, including duodenal and gastric ulcer, non-ulcer dyspepsia and active and chronic gastritis. H.pylori infection is found in more than 90% of duodenal ulcer patients and in around 75% of all peptic ulcer sufferers. H.pylori infection is also more common in gastric cancer patients. The risk of gastric cancer has been estimated to be six-fold higher in H.pylori infected populations than in uninfected populations. H.pylori infections occur in human populations throughout the world. In developed countries, about 50% of the population may have H.pylori infection by the age of 60 years, while only 10-20% of adults in the third decade of life have it. Transmission is most probably by the fecal-oral or oral-oral route. Both invasive and non-invasive methods are used to diagnose H.pylori infection in patients with symptoms of gastrointestinal disease. Invasive methods include culture of gastric biopsy samples, histologic examination of stained biopsy specimens, or direct detection of the urease activity in the biopsy (CLO test). These methods need to obtain a biopsy sample by endoscopy.which is expensive,and usually results discomfort and risk to the patient.noninasive techniques include urea breath tests and serological methods. Urea breath test requires expensive laboratory equipment and moderate radiation exposure. Serologic tests are employed to detect antibodies as human immune response to H.pylori, for example the ELISA and the Western immunoblot. The H.pylori Antibody Rapid Test Card detect antibodies to H.pylori infection in human Whole Blood/Serum/Plasma. It is a noninvasive method and does not use radioactive isotopes. The test is easy to perform and requires no specialized equipment. Visual interpretation provides an accurate qualitative result. It is a useful on-site aid in the diagnosis of H.pylori infection. Diagnosis of H.pylori infection by antibody immunoassay can reduce the number of patients requiring endoscopy. PRINCIPLE The H.pylori Antibody Rapid Test Card is an immunoassay based on the principle of the double antigen-sandwich technique. During testing, a Whole Blood/Serum/Plasma specimen migrates upward by capillary action. The antibodies to H.pylori if present in the specimen will bind to the H.pylori conjugates. The immune complex is then captured on the membrane by the pre-coated H.pylori antigens, and a visible pink-purple line will show up in the test line region indicating a positive result. If antibodies to H.pylori are not present or are present below the detectable level, a pink-purple line will not form in the test line region indicating a negative result. To serve as a procedural control, a pink-purple line will always appear at the control line region, indicating that proper volume of specimen has been added and membrane wicking has occurred. Safety Information The H.pylori Antibody Rapid Test Card is limited to provide a qualitative detection. The intensity of the test line does not necessarily correlate to the concentration of the antibody in the blood. x The results obtained from this test are intended to be an aid in diagnosis only. Each physician must interpret the results in conjunction with the patient’s history, physical findings, and other diagnostic procedures. x A negative test result indicates that antibodies to H.pylori are either not present or at levels undetectable by the test. Direction for Use TEST PROCEDURE 1. Remove the test cassette from the sealed pouch and use it as soon as possible. 2. Place the test cassette on a clean and level surface. 3. For serum or plasma specimen: Hold the dropper vertically and transfer 3 drops of serum or plasma to the specimen well (S) of the test cassette, then start the timer. See illustration below. 4. For whole blood specimens: Hold the dropper vertically and transfer 1 drop of whole blood (approximately 30μl) to the specimen well(S) of the test cassette, then add 2 drops of buffer (approximately 70μl) and start the timer. 5. Read results at 15 minutes. Do not interpret the result after 20 minutes. Other Info STORAGE AND STABILITY x Store as packaged in the sealed pouch at 4-40℃. The kit is stable within the expiration date printed on the label. x Once open the pouch, the test should be used within one hour. Prolonged exposure to hot and humid environment will cause product deterioration.

INTENDED USE The Finecare™ HbA1c Rapid Quantitative Test is a fluorescence immunoassay used along with Finecare™ FIA System for quantitative determination of Hemoglobin A1c in human blood. The test is used as an aid to monitor long-term glycemic status in patients with diabetes mellitus. STORAGE AND STABILITY 1. Store the test kit at 4℃~30℃ up to the expiration date printed on package. 2. If removed from refrigerator, allow the test kit for 30 minutes to return to room temperature before testing. 3. Do not remove the Test Cartridge from the pouch until use. The Test Cartridge should be used within 1 hour once opened.

Finecare™ 2019-nCoV Antigen Test Antigen testing indicates the active infection of 2019-nCoV. For areas with limited PCR resources, antigen testing can be used for aiding in the diagnosis of COVID-19 suspect patients.

Intended Use Scrub Typhus (Tsutsugamushi) IgM & IgG Card is a rapid solid phase immuno-chromatographic assay for the qualitative and differential detection of IgM and IgG antibodies to Scrub Typhus antibodies in human serum / plasma. This test is for in vitro diagnostic use only and is intended as an aid to early diagnosis of Scrub Typhus infection in patient with clinical symptoms. Salient Features Rapid ,visual and qualitative Immunoassay. Differential detection of IgM & IgG antiobodies to Scrub Typhus (Tsutsugamushi) in Human Serum / Plasma. Based on Immunochromatography Technique. See through device for easy interpretation of results. Results with in 20 minutes Shelf life 30 months at 2-30°C Convenient pack size: 20T & 50T. Sensitivity & Specificity: 100% (In house Evaluation)

Intended Use Covid 19 Ag Card Test is designed for in vitro qualitative detection of Covid 19 antigen in human nasopharyngeal, nasal swab specimens. The kit is intended for professional use and as a screening test and is an aid in early diagnosis of SARS COV-2 infection in patients with clinical symptoms. Salient Features Rapid Visual Test for the Qualitative Detection of Covid-19 (SARS-COV-2) antigen in Human nasopharyngeal and nasal swab specimens. Based on Sandwich Immunoassay principle. Results within 20 minutes. Single step test procedure. Evaluated & Validated by ICMR Centre ; Sensitivity -91.5% (<30 CT) & Specificity -100% against RT-PCR. Long Shelf life:30 months at 2-30° C. No Instruments required. Convenient pack sizes . 10T,25T,50T,100T & 200T.

Intended Use Dengue NS1 Antigen self-test is a rapid solid phase immune-chromatographic test for the qualitative detection of Dengue NS1 Ag in human whole blood/serum/plasma. This test is intended to be for home use with self-collected whole blood specimens from individuals aged 18 years or above( or collected by adults for individuals below 18 years of age) as well as for professional use with venous Whole blood/Serum/Plasma samples. This test is for in-vitro diagnostic use only & is designed as an aid in the early diagnosis of dengue infection patients with clinical symptoms. Salient Features Rapid, Visual, Home test for qualitative detection of Dengue NS1 antigen detection in human whole blood/serum/plasma. Finger prick sample can be used. Single test pack. All material to perform the test & its disposal are provided with the kit. Based on Sandwich principle.\ Detection of Dengue in Seronegative stage i.e. from Day 1 of fever. Detection of all 4 serotypes of dengue virus. Reliable diagnosis of both primary and secondary infection. 100% Sensitivity & 100 % Specificity. Shelf life: 30 month at 2-30 °C.